Ozempic and Wegovy are selected for Medicare's price negotiations

Original Article ↗ Hacker News Discussion ↗

Medicare’s move to negotiate prices for Ozempic and Wegovy, blockbuster semaglutide drugs for diabetes and weight loss, is seen as a small but important crack in the U.S. ban on direct drug price bargaining. Commenters contrast America’s high prices and opaque insurer/PBM-driven rebates with far cheaper access in Europe and via compounded or gray‑market sources, debating whether such price setting will actually lower patient costs or just distort incentives for future R&D. Alongside economic and policy concerns, many weigh the medical and ethical stakes of GLP‑1 drugs—how they work, safety of DIY use, their role in addressing obesity versus underlying food and lifestyle problems, and whether relying on medication undermines “willpower” or simply offers necessary harm reduction.

Medicare “negotiations” and policy mechanics

  • Many note Medicare’s new authority is tightly constrained: only a small, specific list of drugs can be “negotiated,” a compromise shaped by pharma lobbying.
  • Several posters argue this isn’t a real negotiation but de facto price setting backed by punitive taxes if manufacturers refuse.
  • Others contrast U.S. practice with other countries’ “purchasing controls” (state buyer simply refuses overpriced drugs) rather than hard price caps, and suggest using QALY-style value thresholds.
  • Debate over whether such price-setting undermines patent-era monopoly incentives vs. merely correcting monopoly abuses.

Drug pricing, patents, and R&D incentives

  • Repeated comparisons: semaglutide is dramatically cheaper in Europe and other markets than in the U.S., despite being the same branded drug.
  • Some cite studies claiming very low manufacturing cost; others criticize those analyses as ignoring R&D, labor, QA, and regulatory overhead.
  • One camp stresses high prices are needed to recoup multi‑billion‑dollar development costs and failed projects; another claims outsized margins mostly enrich shareholders and intermediaries.
  • Cynical takes on why Ozempic/Wegovy (semaglutide) were picked: patents expiring around 2026 vs. longer protection for tirzepatide (Mounjaro/Zepbound), and possible preference for a U.S. company.
  • Proposals include “most‑favored nation” pricing or reference to foreign baskets; critics warn this could restrict access in poor countries or create circular downward pricing.

Clinical effects and the CICO debate

  • Multiple users report GLP‑1s dramatically reduce “food noise,” cravings, and portion sizes, sometimes changing food preferences rather than enabling binge‑and‑purge behavior.
  • Some see them as confirming calories‑in/calories‑out (CICO): they primarily work by lowering intake. Others argue additional metabolic or behavioral effects may matter.
  • Ongoing lay debate: CICO as a physical law vs. its (in)practicality as a weight‑loss prescription given metabolic adaptation, mis‑tracking, and constant hunger.

DIY, compounding, and safety

  • Compounded and “research peptide” semaglutide is widely discussed: much cheaper, but legality depends on FDA‑declared shortages.
  • Significant concern over non‑sterile home mixing and uncertain product quality/dosage; others report using Chinese or Discord‑sourced peptide powders with no evident infections so far.
  • Some recommend reputable compounding pharmacies or clinics; others highlight counterfeit risk even in formal supply chains.

U.S. insurance and system dysfunction

  • Many accounts of insurers abruptly changing formularies, forcing switches between GLP‑1s, or denying coverage even for diabetes indications.
  • Complaints that PBMs and insurers, not just manufacturers, drive U.S. list prices and distort rebates; attempts by manufacturers to cut list prices can allegedly lead to loss of coverage.
  • Frustration that job or plan changes can disrupt ongoing therapy; debate over HIPAA and employer visibility into medications.

Ethical, cultural, and societal angles

  • Some view widespread Ozempic use as dystopian: outsourcing willpower and ignoring root causes (ultra‑processed food, built environment).
  • Others counter that obesity involves addiction‑like biology and hostile food environments; GLP‑1s are likened to nicotine patches or tools like glasses—technology that makes healthy choices feasible.
  • Concerns that focusing on drugs may delay reforms of the food system; others argue harm reduction now is worth it even if upstream fixes lag.

Geopolitics tangent

  • A side thread speculates about U.S. pressure on Danish Novo Nordisk as leverage over Greenland; other commenters find this coordination theory implausible.